The Company has more than doubled revenue from innovative medicines since launching Pivot to Growth in 2023, demonstrating sustained execution and the growing strength of its high-velocity biopharma model
A live webcast of the event and presentation materials will be available on Teva’s Investor Relations website at Events and Presentations, with the webcast beginning at 8:30 a.m. EST today and concluding at 12:30 p.m. EST.
A dedicated media Q&A with Teva leadership will follow the webcast. The session is intended for members of the media, who can register to participate here.
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today will host its first-ever R&D Day, outlining the next phase of the company’s growth and its ambition to generate $6–7 billion in innovative medicines revenue by 2030. President and CEO Richard Francis, together with members of Teva’s executive leadership and R&D teams, will highlight Teva’s advancing pipeline, differentiated R&D model and the potential to launch one innovative medicine per year over the next five years.
“With our Pivot to Growth strategy, we set out to transform Teva,” said Richard Francis, Teva’s President and CEO. “Since then, we have more than doubled our innovative medicines revenue, built a pipeline with more than $10 billion in peak sales potential, and returned to investment grade. We’ve made meaningful progress, driven by teams that are bringing together the speed and agility of a biotech with the scale and capabilities of a global biopharmaceutical company. Our R&D engine and commercial excellence are designed to translate proven science into new medicines, with the potential for one new launch annually through 2030, driving revenue growth, margin expansion and strong cash generation.”
Teva will provide updates on its differentiated R&D approach, late-stage growth drivers and early-stage pipeline assets, in-house antibody discovery capabilities, as well as its commercial and financial capabilities to support its upcoming next wave of innovation and longer-term shareholder value creation. The next wave of growth drivers supporting Teva's growth ambition beyond 2030:
- Anti-IL-15: Phase 2a study in Celiac disease met its primary endpoint, with a Phase 2b study expected to begin in the second half of 2027. In vitiligo, TEV-’408 is advancing into a Phase 2/3 study building on encouraging Phase 1b results. Teva is also evaluating the potential of TEV-’408 in additional indications, including alopecia.
- Anti-PD-1/IL-2 ATTENUKINE™: The investigational asset is currently in Phase 1 development in advanced cancer, with early efficacy signals and a favorable safety profile observed to date.
- Next Generation antibodies: Teva is advancing its early-stage pipeline with next-generation precision antibodies, including anti-TSLP/IL-13 and anti-TL1A/IL-23, applying its antibody-engineering capabilities and understanding of disease biology with a potential to build potential new treatments in in asthma and inflammatory bowel disease.
The presentation is grounded in the fundamentals that enable Teva’s journey:
- Differentiated R&D approach: Focuses on proven science from internal or external sources enabling accelerated development. This aims to build assets with best-in-class potential, including a late-stage pipeline with a potential of more than $10 billion in combined peak sales, subject to regulatory approvals.
- Disciplined decision-making and capital allocation: Fast, data-driven decisions and allocating capital into high-return opportunities. Its targeted and strategic partnerships allow it to expand and accelerate its pipeline.
- Strong commercial capabilities: Deep patient and healthcare understanding, strong analytics and access experience, combined with expertise to drive launch excellence, build markets and help innovative medicines reach the patients who need them.
- Financial strength and capital allocation: In 2026, Teva has returned to an investment grade credit rating. Its disciplined and focused reinvestment funds the pipeline, launches and business development in areas of focus, to continue to create shareholder value.
This approach has already accelerated timelines across our late-stage pipeline, including WELTRUZATM going directly from Phase 1 into Phase 3, ecopipam receiving FDA priority review and advancing anti IL-15 in vitiligo as a seamless Phase 2/3 program later this year.
A biopharma company, by the numbers
Since launching its Pivot to Growth strategy in 2023, Teva has delivered on the commitments with Teva's revenue from innovative medicines more than doubling, with its three key innovative products AUSTEDO® (deutetrabenazine) AJOVY® (fremanezumab-vfrm) and UZEDY® (risperidone) expected to grow more than ~125% by the end of 2026. In addition, Teva has recently launched WELTRUZA™ (olanzapine).
Innovative medicines now make up more than 20% of Teva's revenue, gross margin has improved to ~55%1, and Teva has seven late-stage pipeline assets with high-value potential. The innovative pipeline has grown to ten programs, including two clinical antibodies discovered in-house. Teva’s generics business has been stabilized in recent years, its revenue from biosimilars is expected to double from 2024 to 2026, and Teva has generated more than $6 billion in free cash flow from 2023 to 2025. Teva’s return to investment grade credit ranking provides Teva the financial foundation to fund Teva's next phase.
Financial outlook through 2030:
- Innovative revenue potential of $6–7 billion by 2030
- Innovative gross margins target of above 75%, with the mix shift driving margin expansion
- Total revenue: mid-single-digit growth from 2026 to 2030
- Free cash flow target of more than $3.5 billion by 2030
- Leverage: a clear path to net debt to adjusted EBITDA of 2.0x by the end of 2027
- Capital allocation: a disciplined framework funds the pipeline, launches and business development, along with shareholder returns
Presenters include:
- Richard Francis, President and Chief Executive Officer
- Eric Hughes, MD, PhD, EVP, Global R&D and Chief Medical Officer
- Steffen Nock, PhD, Chief Scientific Officer and Head of Global Discovery and Human Translational Science
- David Gardiner, MD, SVP, Head of Innovative Medicines and Clinical Development
- Chris Fox, EVP, U.S. Commercial and Global Innovative Medicines
- Eli Kalif, EVP, Chief Financial Officer
Webcast and materials
A live webcast and the presentation materials will be available on Teva's Investor Relations website at ir.tevapharm.com/Events-and-Presentations. An archived version will be posted within 24 hours of the event. An interactive digital magazine and press kit is available on tevapharm.com.
Pipeline products are investigational and subject to clinical development and regulatory approval. Peak sales figures are non-risk-adjusted and indicative. Financial measures other than revenue are non-GAAP.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars, and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
